Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):189–194. doi: 10.1097/QAI.0b013e3182926f95

Table 1.

Demographic and Clinical Characteristics

Characteristic Total
(N=563)
CrAg
Positive
(N=32)
CrAg
Negative
(N=531)
p-
value
Demographics
  Female gender 301 16 (50%) 285 (54%) 0.69
  Median age (years) 33 (28–40) 36 (29–41) 33 (28–39) 0.42
HIV History
  Prior known HIV infection 375 17 (53%) 358 (67%) 0.10
  Median CD4-count (cells/uL) 51 (16–171) 25 (8–77) 55 (18–172) 0.02
  ART on admission 104 4 (13%) 100 (19%) 0.37
  Co-trimoxazole on admission 273 13 (41%) 260 (49%) 0.36
  Fluconazole on admission 0 0 0 NA
Fluconazole at discharge * 6 2 (7%) 4 (1%) 0.002
Presenting symptoms**
  Fever 493 29 (91%) 464 (87%) 0.59
  Weight loss >5 kg 409 21 (66%) 388 (73%) 0.36
  Dyspnea 315 18 (56%) 297 (56%) 0.97
Final diagnosis
  Tuberculosis 337 10 (31%) 327 (62%) 0.001
  Unknown diagnosis 96 8 (25%) 88 (16%) 0.22

Data presented as number (%) or median (interquartile range)

*

Fluconazole use at discharge only known for 520 patients

**

Cough present in 100% (parent study inclusion criteria)